Bayer has appointed Nelson Ambrogio as president of its U.S. pPharmaceuticals business, effective May 1, 2026.
Ambrogio has served as president of Bayer's global radiology business since April 2024. In his new role, he will oversee commercial pharmaceutical operations in the U.S. and join the company's Worldwide Markets Leadership Team. Ambrogio previously led Bayer's oncology and women’s healthcare concerns.
Bayer noted that the U.S. is its largest and fastest-growing pharmaceutical market. Its U.S. pharmaceutical portfolio spans prostate cancer, cardiovascular care, and women's healthcare, with a pipeline expansion planned in secondary stroke prevention.
The company also said that Sebastian Guth will continue to oversee the growth of all global markets in his role as chief operating officer of Bayer Pharmaceuticals. Guth will retain his role as president of the Bayer Group in the U.S., according to Bayer.
